MD35Z - Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland - Google Patents

Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland

Info

Publication number
MD35Z
MD35Z MDS20080030A MDS20080030A MD35Z MD 35 Z MD35 Z MD 35Z MD S20080030 A MDS20080030 A MD S20080030A MD S20080030 A MDS20080030 A MD S20080030A MD 35 Z MD35 Z MD 35Z
Authority
MD
Moldova
Prior art keywords
microcalcificates
determined
situ
development
revealed
Prior art date
Application number
MDS20080030A
Other languages
Romanian (ro)
Russian (ru)
Inventor
Василе ЖОВМИР
Симона КЯБУРУ
Наталия РОТАРУ
Original Assignee
Василе ЖОВМИР
Симона КЯБУРУ
Наталия РОТАРУ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Василе ЖОВМИР, Симона КЯБУРУ, Наталия РОТАРУ filed Critical Василе ЖОВМИР
Priority to MDS20080030A priority Critical patent/MD35Z/en
Publication of MD35Y publication Critical patent/MD35Y/en
Publication of MD35Z publication Critical patent/MD35Z/en

Links

Landscapes

  • Apparatus For Radiation Diagnosis (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

The invention refers to medicine, particularly oncology and can be used for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland for determining the treatment.Summary of the invention includes carrying out of clinical, ultrasound and mammographic investigations, carrying out of computer tomography. If clininally are not revealed objective or subjective signs or it is determined presence of serous discharge from the mammary gland duct, at the ultrasound examination are revealed diffuse changes in the glandular tissue, at the mammographic examination are determined up to 5 microcalcificates to 1 cm2, according to Le Gal I-st or II-nd type, according to the Classification of the American College of Radiology (ACR) 1, 2 or 3 and at the computer tomography without pathology and absence of suspicious regional lymph nodes for presence of metastases, it is appreciated a minor risk of development of the noninvasive carcinoma in situ. If clinically there are present inflammation signs or induration with serous or serous-bloody discharge from the mammary gland duct, at the ultrasound examination it is revealed the localized fibroadenomatosis, suspicion of microcalcificates presence, at the mammographic examination there are determined up to 10 microcalcificates to 1 cm2, according to Le Gal III-rd type, according to ACR 4 and at the computer tomography is determined induration, up to 10 microcalcificates to 1 cm2, intraductal papilloma and absence of suspicious regional lymph nodes for presence of matastases, it is appreciated a medium risk of development of the noninvasive carcinoma in situ, and if clinically is determined induration or tumoral formation with bloody discharge, at the ultrasound examination it is revealed the localized fibroadenomatosis or a formation with microcalcificates, at the mammographic examination there are revealed more than 10 microcalcificates to 1 cm2, according to Le Gal IV -V type, according to ACR 5 and at the computer tomography is determined tumor with reduced density or localized fibroadenomatosis, multiple intraductal papillomae, more than 10 microcalcificates to 1 cm2 and absence of suspicious regional lymph nodes for presence of metastases, it is appreciated a major risk of development of the noninvasive carcinoma in situ.
MDS20080030A 2008-12-02 2008-12-02 Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland MD35Z (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDS20080030A MD35Z (en) 2008-12-02 2008-12-02 Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDS20080030A MD35Z (en) 2008-12-02 2008-12-02 Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland

Publications (2)

Publication Number Publication Date
MD35Y MD35Y (en) 2009-06-30
MD35Z true MD35Z (en) 2010-01-31

Family

ID=40942312

Family Applications (1)

Application Number Title Priority Date Filing Date
MDS20080030A MD35Z (en) 2008-12-02 2008-12-02 Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland

Country Status (1)

Country Link
MD (1) MD35Z (en)

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD106C2 (en) * 1993-11-12 1995-06-30 Онкологический Институт Республики Молдова Method of treatment for mamma cancer
MD446G2 (en) * 1995-07-07 1996-11-30 Онкологический Институт Республики Молдова Method for mamma cancer treatment
MD798G2 (en) * 1996-11-15 1998-05-31 Онкологический Институт Республики Молдова Method of the mamma cancer treatment
MD962G2 (en) * 1997-07-24 1998-12-31 Онкологический Институт Республики Молдова Method for radical mastectomy
MD1569G2 (en) * 1999-12-17 2001-06-30 Онкологический Институт Республики Молдова Method of treatment of breast canceeeer in the preoperation period
MD1630G2 (en) * 1999-06-04 2001-09-30 Онкологический Институт Республики Молдова Method of radical mastectomy in breast cancer
EA002054B1 (en) * 1996-10-30 2001-12-24 Эли Лилли Энд Компани Method for preventing breast cancer
EA002933B1 (en) * 1997-11-28 2002-10-31 Масаюки Мацуура Method of wave therapy and apparatus therefor
EA200200943A1 (en) * 2000-03-03 2003-02-27 Фармация Италия С.П.А. HORMONAL THERAPY OF BREAST CANCER
EA003256B1 (en) * 1997-08-29 2003-02-27 Байоджен, Инк. METHOD FOR TREATING MALIGNANT TUMOR BY IN VIVO GENE THERAPY WITH USE OF GENES ENCODING INTERFERON-beta
EA004634B1 (en) * 1996-07-18 2004-06-24 Корнелл Рисерч Фаундейшн, Инк Treatment and diagnosis of cancer
EA005601B1 (en) * 1999-10-06 2005-04-28 Байоджен, Инк. Method of treating a mammal having malignant tumors characterized by abnormally high expression of a proliferation inducing ligand (april) in cells
EA006097B1 (en) * 1999-04-09 2005-08-25 Авентис Фарма С.А. Treating of cancers of docetaxel in combination with recombinant humanized monoclonal anti-her2 antibody
EA006295B1 (en) * 2000-10-02 2005-10-27 Фармация Италия С.П.А. Use of distamycin derivatives for antitumor therapy
EA006709B1 (en) * 2000-06-23 2006-02-24 Фармация Италия С.П.А. Combined therapy against tumors comprising use of substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
EA006684B1 (en) * 2000-06-23 2006-02-24 Фармация Италия С.П.А. Combined therapy against tumors comprising using substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
MD2849G2 (en) * 2005-05-16 2006-04-30 Василе ЖОВМИР Method of mammary cancer treatment to patients of old age
EA008502B1 (en) * 2000-06-23 2007-06-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Combined therapy against tumors comprising submitted acryloyl distamycin derivatives and alkylating agents
MD3248G2 (en) * 2006-06-30 2007-09-30 Василе ЖОВМИР Method of mammary cancer treatment
MD3772G2 (en) * 2008-05-12 2009-07-31 Общественное Медико-Санитарное Учреждение Онкологический Институт Method for treating mammary cancer with metastases
MD3671G2 (en) * 2007-11-02 2009-09-30 Онкологический Институт Республики Молдова Method of subtotal mastectomy in the mammary upper dial cancer
  • 2008

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD106C2 (en) * 1993-11-12 1995-06-30 Онкологический Институт Республики Молдова Method of treatment for mamma cancer
MD446G2 (en) * 1995-07-07 1996-11-30 Онкологический Институт Республики Молдова Method for mamma cancer treatment
EA004634B1 (en) * 1996-07-18 2004-06-24 Корнелл Рисерч Фаундейшн, Инк Treatment and diagnosis of cancer
EA002054B1 (en) * 1996-10-30 2001-12-24 Эли Лилли Энд Компани Method for preventing breast cancer
MD798G2 (en) * 1996-11-15 1998-05-31 Онкологический Институт Республики Молдова Method of the mamma cancer treatment
MD962G2 (en) * 1997-07-24 1998-12-31 Онкологический Институт Республики Молдова Method for radical mastectomy
EA003256B1 (en) * 1997-08-29 2003-02-27 Байоджен, Инк. METHOD FOR TREATING MALIGNANT TUMOR BY IN VIVO GENE THERAPY WITH USE OF GENES ENCODING INTERFERON-beta
EA002933B1 (en) * 1997-11-28 2002-10-31 Масаюки Мацуура Method of wave therapy and apparatus therefor
EA006097B1 (en) * 1999-04-09 2005-08-25 Авентис Фарма С.А. Treating of cancers of docetaxel in combination with recombinant humanized monoclonal anti-her2 antibody
MD1630G2 (en) * 1999-06-04 2001-09-30 Онкологический Институт Республики Молдова Method of radical mastectomy in breast cancer
EA005601B1 (en) * 1999-10-06 2005-04-28 Байоджен, Инк. Method of treating a mammal having malignant tumors characterized by abnormally high expression of a proliferation inducing ligand (april) in cells
MD1569G2 (en) * 1999-12-17 2001-06-30 Онкологический Институт Республики Молдова Method of treatment of breast canceeeer in the preoperation period
EA200200943A1 (en) * 2000-03-03 2003-02-27 Фармация Италия С.П.А. HORMONAL THERAPY OF BREAST CANCER
EA005413B1 (en) * 2000-03-03 2005-02-24 Фармация Италия С.П.А. Breast cancer hormonal therapy
EA006709B1 (en) * 2000-06-23 2006-02-24 Фармация Италия С.П.А. Combined therapy against tumors comprising use of substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites
EA006684B1 (en) * 2000-06-23 2006-02-24 Фармация Италия С.П.А. Combined therapy against tumors comprising using substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
EA008502B1 (en) * 2000-06-23 2007-06-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Combined therapy against tumors comprising submitted acryloyl distamycin derivatives and alkylating agents
EA006295B1 (en) * 2000-10-02 2005-10-27 Фармация Италия С.П.А. Use of distamycin derivatives for antitumor therapy
MD2849G2 (en) * 2005-05-16 2006-04-30 Василе ЖОВМИР Method of mammary cancer treatment to patients of old age
MD3248G2 (en) * 2006-06-30 2007-09-30 Василе ЖОВМИР Method of mammary cancer treatment
MD3671G2 (en) * 2007-11-02 2009-09-30 Онкологический Институт Республики Молдова Method of subtotal mastectomy in the mammary upper dial cancer
MD3772G2 (en) * 2008-05-12 2009-07-31 Общественное Медико-Санитарное Учреждение Онкологический Институт Method for treating mammary cancer with metastases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Liberman L. Cancer Screening with MRI-What Are the Data for Patients at High Risk? New Engl. J. Med., 2005, 35 (5), p. 497-500 *
Sakofaras G.H., Farley D.R. Optimal management of ductal carcinoma in situ of the breast. Surgical Oncology, №12, 2003 *

Also Published As

Publication number Publication date
MD35Y (en) 2009-06-30

Similar Documents

Publication Publication Date Title
Farasat et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics
Yu et al. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component
Girardi et al. Breast ultrasound in 22,131 asymptomatic women with negative mammography
Hatzipantelis et al. Carcinoid tumors of the appendix in children: experience from a tertiary center in northern Greece
Singletary et al. Defining the clinical diagnosis of inflammatory breast cancer
McCord et al. Oral squamous cell carcinoma associated with precursor lesions
Wang et al. Adenoid cystic carcinoma of the breast: Review of the literature and report of two cases
Zhu et al. Differentiation of gastric true leiomyoma from gastric stromal tumor based on biphasic contrast-enhanced computed tomographic findings
Ampil et al. Carcinoma of the axillary tail of Spence: a case series
Leve et al. Recurrent renal cell carcinoma presenting as a cutaneous metastasis: A case report and review of the literature
Alessandrino et al. Imaging surveillance of gastrointestinal stromal tumour: current recommendation by National Comprehensive Cancer Network and European Society of Medical Oncology-European Reference Network for rare adult solid cancers
MD35Z (en) Method for appreciating the risk of development of the noninvasive carcinoma in situ of the mammary gland
Khajotia et al. Unusually large breast tumour in a middle-aged woman
Hudolin et al. Ureteral metastasis of occult breast cancer
Dawood et al. Clinical aspect of inflammatory breast cancer: Diagnosis, criteria, controversy
Xu et al. Mammography-detected ultrasound-negative asymptomatic micro-calcifications in Chinese women: Would it be safe to watch and wait?
Ajkay et al. Fine-needle aspiration cytology in the evaluation of patients with radiographically occult, palpable breast abnormalities
Pradier et al. Differences in breast carcinoma in situ between menopausal and premenopausal women
Solà et al. Sentinel node biopsy in special histologic types of invasive breast cancer
Kumar et al. Primary malignant melanoma of the gall bladder masquerading as xanthogranulomatous cholecystitis
MD24Z (en) Method of differential treatment of noninvasive mammary carcinoma
Loane Benign sclerosing lesions of the breast
Vaidya et al. Abstract S4-2: Targeted intraoperative radiotherapy for early breast cancer: TARGIT-A trial-updated analysis of local recurrence and first analysis of survival
Mullooly et al. Utilizing digital pathology to understand breast epithelial characteristics of benign breast disease among women undergoing diagnostic image-guided breast biopsy
Koelmeyer et al. Abstract P6-12-16: L-Dex surveillance of breast cancer-related lymphoedema: A retrospective study

Legal Events

Date Code Title Description
KA4Y Short-term patent lapsed due to non-payment of fees (with right of restoration)
MM4Y Short-term patent definitely lapsed due to non-payment of fees